124 related articles for article (PubMed ID: 18779749)
41. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
[TBL] [Abstract][Full Text] [Related]
42. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
43. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
44. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Ryschich E; Märten A
J Immunother; 2008 Sep; 31(7):599-606. PubMed ID: 18600184
[TBL] [Abstract][Full Text] [Related]
45. Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.
Tao Y; Lin F; Li T; Xie J; Shen C; Zhu Z
Oncol Res; 2013; 21(6):307-16. PubMed ID: 25198660
[TBL] [Abstract][Full Text] [Related]
46. Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice.
Dong B; Wang L; Nie S; Li X; Xiao Y; Yang L; Meng X; Zhao P; Cui C; Tu L; Lu W; Sun W; Yu Y
Vaccine; 2018 Dec; 36(52):8148-8157. PubMed ID: 30449633
[TBL] [Abstract][Full Text] [Related]
47. Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine.
Zhou F; Yang J; Zhang Y; Liu M; Lang ML; Li M; Chen WR
Clin Cancer Res; 2018 Nov; 24(21):5335-5346. PubMed ID: 30068705
[No Abstract] [Full Text] [Related]
48. Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.
Kraśko JA; Žilionytė K; Darinskas A; Strioga M; Rjabceva S; Zalutsky I; Derevyanko M; Kulchitsky V; Lubitz W; Kudela P; Miseikyte-Kaubriene E; Karaman O; Didenko H; Potebnya H; Chekhun V; Pašukonienė V
Oncol Rep; 2017 Jan; 37(1):171-178. PubMed ID: 27878261
[TBL] [Abstract][Full Text] [Related]
49. Antitumor and adjuvant effects of phagelysates of E.coli in mice with Ehrlich carcinoma.
Gambashidze K; Khorava P; Azaladze T; Kalandarishvili K; Jaiani E; Lasareishvil B; Azaladze A; Tediashvili M
Exp Oncol; 2012 Jul; 34(2):107-11. PubMed ID: 23013762
[TBL] [Abstract][Full Text] [Related]
50. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12.
Zaharoff DA; Hance KW; Rogers CJ; Schlom J; Greiner JW
J Immunother; 2010 Sep; 33(7):697-705. PubMed ID: 20664357
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
Xuan W; Yan Y; Wan M; Wu X; Ji D; Wang L; Lin C; Chen Y; Yu Y; Zhang X
Int Immunopharmacol; 2015 Jul; 27(1):95-103. PubMed ID: 25907246
[TBL] [Abstract][Full Text] [Related]
52. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
[TBL] [Abstract][Full Text] [Related]
53. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapeutic approaches in pancreatic cancer.
Stieler J
Recent Results Cancer Res; 2008; 177():165-77. PubMed ID: 18084958
[TBL] [Abstract][Full Text] [Related]
55. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.
Chouaib S
J Clin Invest; 2003 Mar; 111(5):595-7. PubMed ID: 12618511
[No Abstract] [Full Text] [Related]
56. Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine.
Meng Y; Efimova EV; Hamzeh KW; Darga TE; Mauceri HJ; Fu YX; Kron SJ; Weichselbaum RR
Mol Ther; 2012 May; 20(5):1046-55. PubMed ID: 22334019
[TBL] [Abstract][Full Text] [Related]
57. Bacterial immunostimulants--mechanism of action and clinical application in respiratory diseases.
Rozy A; Chorostowska-Wynimko J
Pneumonol Alergol Pol; 2008; 76(5):353-9. PubMed ID: 19003766
[TBL] [Abstract][Full Text] [Related]
58. Bacteriolytic therapy of experimental pancreatic carcinoma.
Maletzki C; Gock M; Klier U; Klar E; Linnebacher M
World J Gastroenterol; 2010 Jul; 16(28):3546-52. PubMed ID: 20653063
[TBL] [Abstract][Full Text] [Related]
59. Combining bacterial-immunotherapy with therapeutic antibodies: a novel therapeutic concept.
Klier U; Maletzki C; Kreikemeyer B; Klar E; Linnebacher M
Vaccine; 2012 Apr; 30(17):2786-94. PubMed ID: 22342917
[TBL] [Abstract][Full Text] [Related]
60. Advances in immunotherapy for pancreatic cancer: 2013.
DeVito NC; Saif MW
JOP; 2013 Jul; 14(4):347-53. PubMed ID: 23846925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
